Humanin vs Thymosin Beta-4
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
HumaninRecovery & RepairAnti-Aging & Longevity
Thymosin Beta-4- Summary
- Humanin is a mitochondria-derived peptide (MDP) encoded in the 16S rRNA region of the mitochondrial genome. It protects neurons and other cells from apoptosis, improves insulin sensitivity, and declines significantly with age. HNG (S14G-Humanin) is a synthetic analog with 1000x greater potency.
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Half-Life
- ~4–8 hours (HNG)
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 2–8 mg
- 5–10 mg
- Frequency
- 3–5 times per week
- 2x per week (loading), then 1x per week (maintenance)
- Key Benefits
- Neuroprotection against amyloid-beta toxicity (Alzheimer's relevance)
- Inhibits cellular apoptosis
- Improves insulin sensitivity
- Reduces cardiovascular risk markers
- Anti-inflammatory effects
- Correlates with longevity in centenarian studies
- Protects against ischemic injury
- Potential cancer cell apoptosis sensitization
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Side Effects
- Injection site irritation
- Limited human safety data available
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- Stacks With
- —
- —